See how early patient inclusion, integrated regulatory planning, and seamless CRO partnerships can help biotechs accelerate ...
New results from the Phase III MATTERHORN trial show AstraZeneca’s Imfinzi combination reduced the risk of death by 22% versus chemotherapy alone, marking a major advance for patients with resectable ...
This is the Applied Clinical Trials Brief —your fast track to the latest insights in clinical research operations. In under ...
Designing adhesion and durability for biopharmaceuticals in the most extreme cold chain environments.
Gain insight into why early toxicology readiness and strong scientific collaboration with CRO partners are critical to ...
Take a closer look at how agentic AI can automate repetitive monitoring tasks while keeping human oversight central to ...
Gain perspective on how agentic AI can bridge eCOA, EDC, IRT, and CTMS platforms to reduce manual effort and improve ...
Learn how streamlined confidentiality agreements and consistent workflows can speed site activation and improve sponsor-site ...
Praxis Precision Medicines has shared positive data from its Phase III Essential3 clinical trial program (NCT06087276) assessing ulixacaltamide in essential tremor (ET). Across two studies, the small ...
Reliable assay reproducibility is the bedrock of credible clinical trials, particularly in hemostasis diagnostics where ...
Eli Lilly’s Orforglipron Shows Superior Efficacy Across Multiple Phase III Trials in Type 2 Diabetes
Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...
Discover how early site involvement, streamlined training, and AI-driven tools can simplify system complexity and enhance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results